Table 1 Potential driver genetic alterations in both HER2-negative and HER2-positive components of HER2 heterogeneous breast cancers, and in the HER2-negative components only
Sample ID | Potential driver mutations present in both HER2-negative and HER2-positive components | Potential driver mutations restricted to the HER2-negative component | Potential drivers within regions whose amplification was restricted to the HER2-negative component |
|---|---|---|---|
T1 | TP53 (P152L) | Â | FAM83A, MDM4 |
T2 | NP | NP | BRF2, FGFR1, ZNF703, RAB11FIP1, LSM1, DDHD2, WHSC1L1, PPAPDC1B, EEF1A2, ERLIN2, BAG4 |
T3 | TP53 (E258D) | ATRX (splice site dinucleotide substitution) | YWHAZ, MYC, FAM83A |
T4 | ARID1A (R1446*) | Â | BRF2, ZNF703, RAB11FIP1, ERLIN2 |
T5 | TP53 (E286D) | NP | IKBKB, CAMK1D |
T6 | TP53 (R273H), PIK3CA (H1047R) | HER2 (I767M), ETV5 (E60K) | PHGDH |
T8 | PIK3CA (H1047R), CBFB (splice site) | BRAF (P403S), XRCC1 (S236F) | Â |
T9 | TP53 (R282G), PIK3CA (H1047R), MAP2K4 (R110G), MED12 (R2015M) | Â | LMX1B |
T10 | TP53 (S94fs) | NP | CBX3, RAD21 |
T11 | TP53 (G187_E192delLAPPQ) | NRP1 (R767H) | MYC, RAD21 |
T12 | TP53 (T195N), KIT (A755T) | FANCD2 (L1394F) | DSN1 |
T13 | TP53 (S240I) | NP | PIK3CA |